{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:51:16Z","timestamp":1775281876924,"version":"3.50.1"},"publisher-location":"New York, NY","reference-count":81,"publisher":"Springer New York","isbn-type":[{"value":"9781493933457","type":"print"},{"value":"9781493933471","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/978-1-4939-3347-1_1","type":"book-chapter","created":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T09:04:49Z","timestamp":1456304689000},"page":"1-18","source":"Crossref","is-referenced-by-count":106,"title":["Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint"],"prefix":"10.1007","author":[{"given":"Jos\u00e9","family":"Rueff","sequence":"first","affiliation":[]},{"given":"Ant\u00f3nio Sebasti\u00e3o","family":"Rodrigues","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,2,25]]},"reference":[{"key":"1_CR1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615\u2013627","journal-title":"Annu Rev Med"},{"key":"1_CR2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2174\/138920112799857549","volume":"13","author":"AS Rodrigues","year":"2012","unstructured":"Rodrigues AS, Dinis J, Gromicho M, Martins M, Laires A, Rueff J (2012) Genomics and cancer drug resistance. Curr Pharm Biotechnol 13:651\u2013673","journal-title":"Curr Pharm Biotechnol"},{"key":"1_CR3","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13:714\u2013726","journal-title":"Nat Rev Cancer"},{"key":"1_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","volume":"121","author":"R Kim","year":"2007","unstructured":"Kim R, Emi M, Tanabe K (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121:1\u201314","journal-title":"Immunology"},{"key":"1_CR5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"DB Longley","year":"2005","unstructured":"Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275\u2013292","journal-title":"J Pathol"},{"key":"1_CR6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1200\/JOP.2011.000500","volume":"8","author":"RA Cooper","year":"2012","unstructured":"Cooper RA, Straus DJ (2012) Clinical guidelines, the politics of value, and the practice of medicine: physicians at the crossroads. J Oncol Pract 8:233\u2013235","journal-title":"J Oncol Pract"},{"key":"1_CR7","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.1208\/aapsj080112","volume":"8","author":"FP Guengerich","year":"2006","unstructured":"Guengerich FP (2006) Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 8:E101\u2013E111","journal-title":"AAPS J"},{"key":"1_CR8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/FPC.0b013e32835c2ddf","volume":"23","author":"BB Palma","year":"2013","unstructured":"Palma BB, Silva ESM, Urban P, Rueff J, Kranendonk M (2013) Functional characterization of eight human CYP1A2 variants: the role of cytochrome b5. Pharmacogenet Genomics 23:41\u201352","journal-title":"Pharmacogenet Genomics"},{"key":"1_CR9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.6004\/jnccn.2009.0014","volume":"7","author":"MJ Higgins","year":"2009","unstructured":"Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V (2009) Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J Natl Compr Canc Netw 7:203\u2013213","journal-title":"J Natl Compr Canc Netw"},{"key":"1_CR10","first-page":"105","volume":"1805","author":"A Marusyk","year":"2010","unstructured":"Marusyk A, Polyak K (2010) Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 1805:105\u2013117","journal-title":"Biochim Biophys Acta"},{"key":"1_CR11","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1172\/JCI60534","volume":"121","author":"K Polyak","year":"2011","unstructured":"Polyak K (2011) Heterogeneity in breast cancer. J Clin Invest 121:3786\u20133788","journal-title":"J Clin Invest"},{"key":"1_CR12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-pathol-121808-102113","volume":"5","author":"JJ Salk","year":"2010","unstructured":"Salk JJ, Fox EJ, Loeb LA (2010) Mutational heterogeneity in human cancers: origin and consequences. Annu Rev Pathol 5:51\u201375","journal-title":"Annu Rev Pathol"},{"key":"1_CR13","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2741\/3819","volume":"16","author":"BC Baguley","year":"2011","unstructured":"Baguley BC (2011) The paradox of cancer cell apoptosis. Front Biosci (Landmark Ed) 16:1759\u20131767","journal-title":"Front Biosci (Landmark Ed)"},{"key":"1_CR14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature12625","volume":"501","author":"RA Burrell","year":"2013","unstructured":"Burrell RA, McGranahan N, Bartek J, Swanton C (2013) The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501:338\u2013345","journal-title":"Nature"},{"key":"1_CR15","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883\u2013892","journal-title":"N Engl J Med"},{"key":"1_CR16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.semcancer.2012.04.006","volume":"22","author":"Z Castano","year":"2012","unstructured":"Castano Z, Fillmore CM, Kim CF, McAllister SS (2012) The bed and the bugs: interactions between the tumor microenvironment and cancer stem cells. Semin Cancer Biol 22:462\u2013470","journal-title":"Semin Cancer Biol"},{"key":"1_CR17","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1101\/gad.1609907","volume":"21","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, Settleman J (2007) Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21:3214\u20133231","journal-title":"Genes Dev"},{"key":"1_CR18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/jpm3030124","volume":"3","author":"LM Fleck","year":"2013","unstructured":"Fleck LM (2013) \u201cJust caring\u201d: can we afford the ethical and economic costs of circumventing cancer drug resistance? J Pers Med 3:124\u2013143","journal-title":"J Pers Med"},{"key":"1_CR19","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/carcin\/21.5.857","volume":"21","author":"IB Weinstein","year":"2000","unstructured":"Weinstein IB (2000) Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 21:857\u2013864","journal-title":"Carcinogenesis"},{"key":"1_CR20","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-07-3293","volume":"68","author":"IB Weinstein","year":"2008","unstructured":"Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68:3077\u20133080, discussion 3080","journal-title":"Cancer Res"},{"key":"1_CR21","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ncponc0558","volume":"3","author":"IB Weinstein","year":"2006","unstructured":"Weinstein IB, Joe AK (2006) Mechanisms of disease: oncogene addiction\u2014a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3:448\u2013457","journal-title":"Nat Clin Pract Oncol"},{"key":"1_CR22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","volume":"297","author":"IB Weinstein","year":"2002","unstructured":"Weinstein IB (2002) Cancer. Addiction to oncogenes\u2014the Achilles heal of cancer. Science 297:63\u201364","journal-title":"Science"},{"key":"1_CR23","doi-asserted-by":"crossref","first-page":"120066","DOI":"10.1098\/rsob.120066","volume":"2","author":"P Borst","year":"2012","unstructured":"Borst P (2012) Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol 2:120066","journal-title":"Open Biol"},{"key":"1_CR24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fphar.2012.00149","volume":"3","author":"SD Silva da","year":"2012","unstructured":"da Silva SD, Hier M, Mlynarek A, Kowalski LP, Alaoui-Jamali MA (2012) Recurrent oral cancer: current and emerging therapeutic approaches. Front Pharmacol 3:149","journal-title":"Front Pharmacol"},{"key":"1_CR25","first-page":"97","volume":"4","author":"JE Kim","year":"2013","unstructured":"Kim JE, Leung E, Baguley BC, Finlay GJ (2013) Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines. Front Genet 4:97","journal-title":"Front Genet"},{"key":"1_CR26","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14728222.2012.718330","volume":"16","author":"JC Tien","year":"2012","unstructured":"Tien JC, Xu J (2012) Steroid receptor coactivator-3 as a potential molecular target for cancer therapy. Expert Opin Ther Targets 16:1085\u20131096","journal-title":"Expert Opin Ther Targets"},{"key":"1_CR27","doi-asserted-by":"crossref","first-page":"664","DOI":"10.7150\/ijbs.7.664","volume":"7","author":"G Ma","year":"2011","unstructured":"Ma G, Ren Y, Wang K, He J (2011) SRC-3 has a role in cancer other than as a nuclear receptor coactivator. Int J Biol Sci 7:664\u2013672","journal-title":"Int J Biol Sci"},{"key":"1_CR28","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.2174\/13816128113199990493","volume":"19","author":"RK Vadlapatla","year":"2013","unstructured":"Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK (2013) Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes. Curr Pharm Des 19:7126\u20137140","journal-title":"Curr Pharm Des"},{"key":"1_CR29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10555-007-9042-6","volume":"26","author":"RW Robey","year":"2007","unstructured":"Robey RW, Polgar O, Deeken J, To KW, Bates SE (2007) ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 26:39\u201357","journal-title":"Cancer Metastasis Rev"},{"key":"1_CR30","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/sj.bjc.6604213","volume":"98","author":"C Lemos","year":"2008","unstructured":"Lemos C, Jansen G, Peters GJ (2008) Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br J Cancer 98:857\u2013862","journal-title":"Br J Cancer"},{"key":"1_CR31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1124\/mol.114.096065","volume":"87","author":"KA Jung","year":"2015","unstructured":"Jung KA, Choi BH, Kwak MK (2015) The c-MET\/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP\/ABCG2 expression. Mol Pharmacol 87:465\u2013476","journal-title":"Mol Pharmacol"},{"key":"1_CR32","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/blood.V78.3.586.586","volume":"78","author":"JP Marie","year":"1991","unstructured":"Marie JP, Zittoun R, Sikic BI (1991) Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78:586\u2013592","journal-title":"Blood"},{"key":"1_CR33","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood.V91.12.4480","volume":"91","author":"O Legrand","year":"1998","unstructured":"Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP (1998) Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 91:4480\u20134488","journal-title":"Blood"},{"key":"1_CR34","first-page":"711","volume":"85","author":"C Wuchter","year":"2000","unstructured":"Wuchter C, Leonid K, Ruppert V, Schrappe M, Buchner T, Schoch C, Haferlach T, Harbott J, Ratei R, Dorken B, Ludwig WD (2000) Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 85:711\u2013721","journal-title":"Haematologica"},{"key":"1_CR35","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1158\/1078-0432.CCR-04-0795","volume":"10","author":"Z Benderra","year":"2004","unstructured":"Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP, Legrand O (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 10:7896\u20137902","journal-title":"Clin Cancer Res"},{"key":"1_CR36","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/sj.leu.2404692","volume":"21","author":"D Steinbach","year":"2007","unstructured":"Steinbach D, Legrand O (2007) ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia 21:1172\u20131176","journal-title":"Leukemia"},{"key":"1_CR37","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/sj.leu.2402806","volume":"17","author":"D Steinbach","year":"2003","unstructured":"Steinbach D, Furchtbar S, Sell W, Lengemann J, Hermann J, Zintl F, Sauerbrey A (2003) Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML. Leukemia 17:470\u2013471","journal-title":"Leukemia"},{"key":"1_CR38","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3892\/or.2012.2153","volume":"29","author":"M Gromicho","year":"2013","unstructured":"Gromicho M, Magalhaes M, Torres F, Dinis J, Fernandes AR, Rendeiro P, Tavares P, Laires A, Rueff J, Sebastiao RA (2013) Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib. Oncol Rep 29:741\u2013750","journal-title":"Oncol Rep"},{"key":"1_CR39","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3109\/10428194.2011.584005","volume":"52","author":"M Gromicho","year":"2011","unstructured":"Gromicho M, Dinis J, Magalh\u00e3es M, Fernandes A, Tavares P, Laires A, Rueff J, Rodrigues A (2011) Development of imatinib and dasatinib resistance: dynamics of the drug transporters expression ABCB1, ABCC1, ABCG2, MVP and SLC22A1. Leuk Lymphoma 52:1980\u20131990","journal-title":"Leuk Lymphoma"},{"key":"1_CR40","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481:306\u2013313","journal-title":"Nature"},{"key":"1_CR41","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.18632\/oncotarget.3085","volume":"6","author":"K Ohta","year":"2015","unstructured":"Ohta K, Hoshino H, Wang J, Ono S, Iida Y, Hata K, Huang SK, Colquhoun S, Hoon DS (2015) MicroRNA-93 activates c-Met\/PI3K\/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget 6:3211\u20133224","journal-title":"Oncotarget"},{"key":"1_CR42","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12251","volume":"77","author":"S Haenisch","year":"2014","unstructured":"Haenisch S, Werk AN, Cascorbi I (2014) MicroRNAs and their relevance to ABC transporters. Br J Clin Pharmacol 77:587\u2013596","journal-title":"Br J Clin Pharmacol"},{"key":"1_CR43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cdp.2007.07.001","volume":"31","author":"S Silva","year":"2007","unstructured":"Silva S, Moita R, Azevedo A, Gouveia R, Manita I, Pina J, Rueff J, Gaspar J (2007) Menopausal age and XRCC1 gene polymorphisms: role in breast cancer risk. Cancer Detect Prev 31:303\u2013309","journal-title":"Cancer Detect Prev"},{"key":"1_CR44","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1089\/thy.2009.0099","volume":"19","author":"HN Bastos","year":"2009","unstructured":"Bastos HN, Antao MR, Silva SN, Azevedo AP, Manita I, Teixeira V, Pina JE, Gil OM, Ferreira TC, Limbert E, Rueff J, Gaspar JF (2009) Association of polymorphisms in genes of the homologous recombination DNA repair pathway and thyroid cancer risk. Thyroid 19:1067\u20131075","journal-title":"Thyroid"},{"key":"1_CR45","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/1471-2407-9-344","volume":"9","author":"J Conde","year":"2009","unstructured":"Conde J, Silva S, Azevedo A, Teixeira V, Pina J, Rueff J, Gaspar J (2009) Association of common variants in mismatch repair genes and breast cancer susceptibility: a multigene study. BMC Cancer 9:344","journal-title":"BMC Cancer"},{"key":"1_CR46","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3892\/or.2013.2702","volume":"30","author":"LS Santos","year":"2013","unstructured":"Santos LS, Gomes BC, Gouveia R, Silva SN, Azevedo AP, Camacho V, Manita I, Gil OM, Ferreira TC, Limbert E, Rueff J, Gaspar JF (2013) The role of CCNH Val270Ala (rs2230641) and other nucleotide excision repair polymorphisms in individual susceptibility to well-differentiated thyroid cancer. Oncol Rep 30:2458\u20132466","journal-title":"Oncol Rep"},{"key":"1_CR47","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3892\/or.2012.1975","volume":"28","author":"LS Santos","year":"2012","unstructured":"Santos LS, Branco SC, Silva SN, Azevedo AP, Gil OM, Manita I, Ferreira TC, Limbert E, Rueff J, Gaspar JF (2012) Polymorphisms in base excision repair genes and thyroid cancer risk. Oncol Rep 28:1859\u20131868","journal-title":"Oncol Rep"},{"key":"1_CR48","first-page":"1079","volume":"24","author":"BC Gomes","year":"2010","unstructured":"Gomes BC, Silva SN, Azevedo AP, Manita I, Gil OM, Ferreira TC, Limbert E, Rueff J, Gaspar JF (2010) The role of common variants of non-homologous end-joining repair genes XRCC4, LIG4 and Ku80 in thyroid cancer risk. Oncol Rep 24:1079\u20131085","journal-title":"Oncol Rep"},{"key":"1_CR49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.canep.2009.11.002","volume":"34","author":"SN Silva","year":"2010","unstructured":"Silva SN, Tomar M, Paulo C, Gomes BC, Azevedo AP, Teixeira V, Pina JE, Rueff J, Gaspar JF (2010) Breast cancer risk and common single nucleotide polymorphisms in homologous recombination DNA repair pathway genes XRCC2, XRCC3, NBS1 and RAD51. Cancer Epidemiol 34:85\u201392","journal-title":"Cancer Epidemiol"},{"key":"1_CR50","doi-asserted-by":"crossref","unstructured":"Silva SN, Gomes BC, Rueff J, Gaspar JF (2011) DNA repair perspectives in thyroid and breast cancer: the role of DNA repair polymorphisms. In: Vengrova S (ed) DNA repair and human health. InTech. doi:10.5772\/22944","DOI":"10.5772\/22944"},{"key":"1_CR51","doi-asserted-by":"crossref","unstructured":"Rodrigues AS, Gomes BC, Martins C, Gromicho M, Oliveira NG, Guerreiro PS, Rueff J (2013) DNA repair and resistance to cancer therapy. In: Chen C (ed) DNA repair and resistance to cancer therapy, new research directions in DNA repair. Intech. doi:10.5772\/53952","DOI":"10.5772\/53952"},{"key":"1_CR52","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","volume":"26","author":"DP Atchley","year":"2008","unstructured":"Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282\u20134288","journal-title":"J Clin Oncol"},{"key":"1_CR53","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clbc.2014.08.003","volume":"15","author":"S Akashi-Tanaka","year":"2015","unstructured":"Akashi-Tanaka S, Watanabe C, Takamaru T, Kuwayama T, Ikeda M, Ohyama H, Mori M, Yoshida R, Hashimoto R, Terumasa S, Enokido K, Hirota Y, Okuyama H, Nakamura S (2015) BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy. Clin Breast Cancer 15:80\u201385","journal-title":"Clin Breast Cancer"},{"key":"1_CR54","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1158\/1078-0432.CCR-14-1165","volume":"20","author":"F Dietlein","year":"2014","unstructured":"Dietlein F, Reinhardt HC (2014) Molecular pathways: exploiting tumor-specific molecular defects in DNA repair pathways for precision cancer therapy. Clin Cancer Res 20:5882\u20135887","journal-title":"Clin Cancer Res"},{"issue":"761","key":"1_CR55","first-page":"763","volume":"386","author":"KW Kinzler","year":"1997","unstructured":"Kinzler KW, Vogelstein B (1997) Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386(761):763","journal-title":"Nature"},{"key":"1_CR56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-94-007-4590-2_2","volume-title":"DNA repair of cancer stem cells","author":"TS Dexheimer","year":"2013","unstructured":"Dexheimer TS (2013) DNA repair pathways and mechanisms. In: Mathews LA, Cabarcas SM, Hurt EM (eds) DNA repair of cancer stem cells. Springer, Dordrecht, Netherlands, pp 19\u201332. doi: 10.1007\/978-94-007-4590-2_2"},{"key":"1_CR57","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.tig.2011.05.007","volume":"27","author":"B Lehner","year":"2011","unstructured":"Lehner B (2011) Molecular mechanisms of epistasis within and between genes. Trends Genet 27:323\u2013331","journal-title":"Trends Genet"},{"key":"1_CR58","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1186\/s13058-014-0494-7","volume":"16","author":"PG Alluri","year":"2014","unstructured":"Alluri PG, Speers C, Chinnaiyan AM (2014) Estrogen receptor mutations and their role in breast cancer progression. Breast Cancer Res 16:494","journal-title":"Breast Cancer Res"},{"key":"1_CR59","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/ijms14010108","volume":"14","author":"R Garcia-Becerra","year":"2012","unstructured":"Garcia-Becerra R, Santos N, Diaz L, Camacho J (2012) Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 14:108\u2013145","journal-title":"Int J Mol Sci"},{"key":"1_CR60","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1745-7254.2006.00315.x","volume":"27","author":"J Yan","year":"2006","unstructured":"Yan J, Tsai SY, Tsai MJ (2006) SRC-3\/AIB1: transcriptional coactivator in oncogenesis. Acta Pharmacol Sin 27:387\u2013394","journal-title":"Acta Pharmacol Sin"},{"key":"1_CR61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.drup.2012.01.008","volume":"15","author":"RH Wilting","year":"2012","unstructured":"Wilting RH, Dannenberg J-H (2012) Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat 15:21\u201338","journal-title":"Drug Resist Updat"},{"key":"1_CR62","doi-asserted-by":"publisher","DOI":"10.4172\/2157-2518.S8-006","author":"F Theodora","year":"2014","unstructured":"Theodora F (2014) Tumor plasticity driven by spatial micro-heterogeneity in the tumor microenvironment contributes to therapy resistance. J Carcinog Mutagen. doi: 10.4172\/2157-2518.S8-006","journal-title":"J Carcinog Mutagen"},{"key":"1_CR63","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.semcancer.2013.08.007","volume":"23","author":"V Catalano","year":"2013","unstructured":"Catalano V, Turdo A, Di Franco S, Dieli F, Todaro M, Stassi G (2013) Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol 23:522\u2013532","journal-title":"Semin Cancer Biol"},{"key":"1_CR64","first-page":"1408","volume":"58","author":"JM Brown","year":"1998","unstructured":"Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58:1408\u20131416","journal-title":"Cancer Res"},{"key":"1_CR65","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500\u2013504","journal-title":"Nature"},{"key":"1_CR66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3233\/CBM-2011-0204","volume":"9","author":"S Srivastava","year":"2010","unstructured":"Srivastava S, Grizzle WE (2010) Biomarkers and the genetics of early neoplastic lesions. Cancer Biomark 9:41\u201364","journal-title":"Cancer Biomark"},{"key":"1_CR67","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1086\/504090","volume":"78","author":"F Weber","year":"2006","unstructured":"Weber F, Shen L, Fukino K, Patocs A, Mutter GL, Caldes T, Eng C (2006) Total-genome analysis of BRCA1\/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation. Am J Hum Genet 78:961\u2013972","journal-title":"Am J Hum Genet"},{"key":"1_CR68","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/gut.48.5.594","volume":"48","author":"RJ Playford","year":"2001","unstructured":"Playford RJ (2001) Landscaper seeks remunerative position. Gut 48:594\u2013595","journal-title":"Gut"},{"key":"1_CR69","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339:1546\u20131558","journal-title":"Science"},{"key":"1_CR70","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"N Cgar","year":"2012","unstructured":"Cgar N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61\u201370","journal-title":"Nature"},{"key":"1_CR71","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674","journal-title":"Cell"},{"key":"1_CR72","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cell.2011.03.026","volume":"145","author":"DA Haber","year":"2011","unstructured":"Haber DA, Gray NS, Baselga J (2011) The evolving war on cancer. Cell 145:19\u201324","journal-title":"Cell"},{"key":"1_CR73","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1126\/science.331.6024.1542","volume":"331","author":"J Kaiser","year":"2011","unstructured":"Kaiser J (2011) Combining targeted drugs to stop resistant tumors. Science 331:1542\u20131545","journal-title":"Science"},{"key":"1_CR74","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48\u201358","journal-title":"Nat Rev Cancer"},{"key":"1_CR75","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/onc.2014.314","volume":"34","author":"P Ramos","year":"2015","unstructured":"Ramos P, Bentires-Alj M (2015) Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene 34:3617\u20133626","journal-title":"Oncogene"},{"key":"1_CR76","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1073\/pnas.0712345105","volume":"105","author":"S Jones","year":"2008","unstructured":"Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J, Markowitz SD (2008) Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 105:4283\u20134288","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR77","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1073\/pnas.1221068110","volume":"110","author":"C Tomasetti","year":"2013","unstructured":"Tomasetti C, Vogelstein B, Parmigiani G (2013) Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc Natl Acad Sci U S A 110:1999\u20132004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR78","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","volume":"486","author":"LA Diaz Jr","year":"2012","unstructured":"Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537\u2013540","journal-title":"Nature"},{"key":"1_CR79","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00747","volume":"2","author":"I Bozic","year":"2013","unstructured":"Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, Moon YS, Yaqubie A, Kelly N, Le DT, Lipson EJ, Chapman PB, Diaz LA Jr, Vogelstein B, Nowak MA (2013) Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2:e00747","journal-title":"eLife"},{"key":"1_CR80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004423","volume":"4","author":"NL Komarova","year":"2009","unstructured":"Komarova NL, Katouli AA, Wodarz D (2009) Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia. PLoS One 4:e4423","journal-title":"PLoS One"},{"issue":"11","key":"1_CR81","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.15252\/emmm.201404033","volume":"6","author":"B Polzer","year":"2014","unstructured":"Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A, Andergassen U, Meier-Stiegen F, Czyz ZT, Alberter B, Treitschke S, Schamberger T, Sergio M, Bregola G, Doffini A, Gianni S, Calanca A, Signorini G, Bolognesi C, Hartmann A, Fasching PA, Sandri MT, Rack B, Fehm T, Giorgini G, Manaresi N, Klein CA (2014) Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med 6(11):1371\u20131386","journal-title":"EMBO Mol Med"}],"container-title":["Methods in Molecular Biology","Cancer Drug Resistance"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-3347-1_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T01:06:41Z","timestamp":1600218401000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-3347-1_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9781493933457","9781493933471"],"references-count":81,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-3347-1_1","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}